Showing results (91-100 of 142) with videos related to

Sort By:
Pageof 15
Cancers|July 18, 2020
Clinical, Hematologic, Biologic and Molecular Characteristics of Patients with Myeloproliferative Neoplasms and a Chronic Myelomonocytic Leukemia-Like PhenotypeSonja Heibl, Bettina Gisslinger, Eva Jäger, et al.
Leukemia|May 21, 2021
Efficacy and safety of a novel dosing strategy for ruxolitinib in the treatment of patients with myelofibrosis and anemia: the REALISE phase 2 studyFrancisco Cervantes, David M Ross, Atanas Radinoff, et al.
British Journal of Haematology|June 29, 2011
Lenalidomide downregulates the cell survival factor, interferon regulatory factor-4, providing a potential mechanistic link for predicting responseAntonia Lopez-Girona, Daniel Heintel, Ling-Hua Zhang, et al.
American Journal of Hematology|January 11, 2022
PD-L1 overexpression correlates with JAK2-V617F mutational burden and is associated with 9p uniparental disomy in myeloproliferative neoplasmsJelena D Milosevic Feenstra, Roland Jäger, Fiorella Schischlik, et al.
Blood|October 4, 2012
Development and validation of an International Prognostic Score of thrombosis in World Health Organization-essential thrombocythemia (IPSET-thrombosis)Tiziano Barbui, Guido Finazzi, Alessandra Carobbio, et al.
BMC Cancer|October 22, 2018
Impact of renal impairment on outcomes after autologous stem cell transplantation in multiple myeloma: a multi-center, retrospective cohort studyMarlies Antlanger, Tobias Dust, Thomas Reiter, et al.
Blood|May 3, 2011
Genome integrity of myeloproliferative neoplasms in chronic phase and during disease progressionThorsten Klampfl, Ashot Harutyunyan, Tiina Berg, et al.
Blood|April 18, 2013
Revised response criteria for polycythemia vera and essential thrombocythemia: an ELN and IWG-MRT consensus projectGiovanni Barosi, Ruben Mesa, Guido Finazzi, et al.
American Journal of Hematology|May 26, 2017
Pre-fibrotic/early primary myelofibrosis vs. WHO-defined essential thrombocythemia: The impact of minor clinical diagnostic criteria on the outcome of the diseaseGeorg Jeryczynski, Jürgen Thiele, Bettina Gisslinger, et al.
Blood|August 12, 2015
Ropeginterferon alfa-2b, a novel IFNα-2b, induces high response rates with low toxicity in patients with polycythemia veraHeinz Gisslinger, Oleh Zagrijtschuk, Veronika Buxhofer-Ausch, et al.
Pageof 15